Immutep (ASX:IMM), a company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, has announced what it describes as "encouraging final data" from its phase one INSIGHT-004 study. …
Latest Video
New Stories
-
Omico appoints Richard Vines as new Chair as it strengthens national precision oncology agenda
October 23, 2025 - - Latest News -
Island Pharmaceuticals secures FDA response date for Galidesivir approval pathway
October 23, 2025 - - Australian Biotech -
Noxopharm granted first US patent for Sofra immune-modulation platform
October 23, 2025 - - Australian Biotech -
4DMedical secures Stanford as first commercial site and expands AstraZeneca partnership in Brazil
October 23, 2025 - - Australian Biotech -
ImpediMed accelerates growth strategy on strong results and expanding market reach
October 23, 2025 - - Australian Biotech -
Clarity Pharmaceuticals’ copper theranostics platform delivers superior prostate cancer imaging results
October 23, 2025 - - Australian Biotech -
Starpharma receives upfront payment from Genentech, launching oncology collaboration
October 23, 2025 - - Australian Biotech